s**********9
发帖数: 846 | 1 “Feuerstein-Ratain rule” works again for kerx. | v**********m
发帖数: 5516 | 2 what does the rule mean?
F OK-> failure?
【在 s**********9 的大作中提到】
: “Feuerstein-Ratain rule” works again for kerx.
| s**********9
发帖数: 846 | 3 http://seekingalpha.com/article/312581-why-perifosine-phase-3-t
【在 v**********m 的大作中提到】
: what does the rule mean?
: F OK-> failure?
| v**********m
发帖数: 5516 | | C********k
发帖数: 560 | | d******8
发帖数: 1972 | | s**********9
发帖数: 846 | 7 好像年底还有一个phaseIII。
Mr. Bentsur commented further, "With approximately $31 million in cash as of
March 31, 2012, and a well-controlled burn rate, we plan to focus our
resources on the pending completion of the Zerenex (ferric citrate) long-
term Phase 3 study for end stage renal disease (ESRD) patients with
hyperphosphatemia, expected in the fourth quarter of 2012, and the New Drug
Application (NDA) filing for Zerenex which will hopefully follow shortly
thereafter."
到9，10 月可以搞搞？
【在 d******8 的大作中提到】
: 敢捞底吗？觉得这个公司基本死掉了
| D******9
发帖数: 2665 | | B*****e
发帖数: 2413 | 9 KERX mainly relies on Perifosine. Theoretically
Perifosine looks charmimg, but phase III indicates it is
not successful.
If you want to bottom it, it is better to bottom AEZS
but not Kerx because AEZS has their own candidate
compounds.
million in cash as
of
plan to focus our
(ferric citrate) long-
patients with
2012, and the New
Drug
hopefully follow shortly
【在 s**********9 的大作中提到】
: 好像年底还有一个phaseIII。
: Mr. Bentsur commented further, "With approximately $31 million in cash as of
: March 31, 2012, and a well-controlled burn rate, we plan to focus our
: resources on the pending completion of the Zerenex (ferric citrate) long-
: term Phase 3 study for end stage renal disease (ESRD) patients with
: hyperphosphatemia, expected in the fourth quarter of 2012, and the New Drug
: Application (NDA) filing for Zerenex which will hopefully follow shortly
: thereafter."
: 到9，10 月可以搞搞？
| D******9
发帖数: 2665 | 10 AEZS， 现在市值70米令， 手里还有40多米令现金， PIPELINE里有几个DRUG
CANDIDATES,看看会不会反弹到1刀？ |
|
